A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Active:	Yes
Cancer Type:	Cancer-Related Syndrome Leukemia Myelodysplastic Syndromes (MDS)	NCT ID:	NCT05490446
Trial Phases:	Phase II	Protocol IDs:	AG946-C-002 (primary) NCI-2023-00894 2022-500609-42-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Agios Pharmaceuticals
NCI Full Details:	http://clinicaltrials.gov/show/NCT05490446

Summary

This purpose of this study is to establish proof of concept of tebapivat in participants
with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion
independence (TI) in participants with LR-MDS in phase 2b.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.